Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy

Journal of Clinical Oncology

Volumn 27, Issue 20, 2009, Pages 3290-3296

  Baumann, Pia ^a   Nyman, Jan ^a   Hoyer, Morten ^a   Wennberg, Berit ^a   Gagliardi, Giovanna ^a   Lax, Ingmar ^a   Drugge, Ninni ^a   Ekberg, Lars ^a   Friesland, Signe ^a   Johansson, Karl Axel ^a   Lund, Jo Åsmund ^a   Morhed, Elisabeth ^a   Nilsson, Kristina ^a   Levin, Nina ^a   Paludan, Merete ^a   Sederholm, Christer ^a   Traberg, Anders ^a   Wittgren, Lena ^a   Lewensohn, Rolf ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LOCAL METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; NORWAY; PRIORITY JOURNAL; RADIATION DOSE; REGIONAL METASTASIS; STEREOTACTIC BODY RADIATION THERAPY; SWEDEN; TOXICITY; TREATMENT FAILURE; DISEASE FREE SURVIVAL; DYSPNEA; FATIGUE; FIBROSIS; LUNG SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PROSPECTIVE STUDY; RADIOSURGERY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DYSPNEA; FATIGUE; FEMALE; FIBROSIS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLEURAL EFFUSION; PROSPECTIVE STUDIES; RADIOSURGERY; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 70249108166     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.5681     Document Type: Article

References (33)

1. Chang MY, Sugarbaker DJ: Surgery for early stage non-small cell lung cancer. Semin Surg Oncol 21:74-84, 2003
2. Martini N, Bains MS, Burt ME, et al: Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120-129, 1995
3. Sweden Tnlcri: The national lung cancer register in Sweden. http://www.roc.se
4. Dosoretz DE, Galmarini D, Rubenstein JH, et al: Local control in medically inoperable lung cancer: An analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys 27:507-516, 1993
5. Qiao X, Tullgren O, Lax I, et al: The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 41:1-11, 2003
6. Bradley J: A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. Semin Oncol 32:S111-S1113, 2005
7. Lax I: Target dose versus extratarget dose in stereotactic radiosurgery. Acta Oncol 32:453-457, 1993
8. Lax I, Blomgren H, Naslund I, et al: Stereotactic radiotherapy of malignancies in the abdomen: Methodological aspects. Acta Oncol 33:677-683, 1994
9. Hof H, Muenter M, Oetzel D, et al: Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC). Cancer 110:148-155, 2007
10. McGarry RC, Papiez L, Williams M, et al: Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: Phase I study. Int J Radiat Oncol Biol Phys 63:1010-1015, 2005
11. Nyman J, Johansson KA, Hulten U: Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients. Lung Cancer 51:97-103, 2006
12. Onishi H, Shirato H, Nagata Y, et al: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2:S94-S100, 2007
13. Timmerman RD, Park C, Kavanagh BD: The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol 2:S101-S112, 2007
14. Zimmermann FB, Geinitz H, Schill S, et al: Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 45:796-801, 2006
15. Morten Hoyer HR, Ander Traberg hansen, Lars Ohlhuis, et al: Prospective study on stereotactic radiotherapy of limited-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 66:128-135, 2006
16. Aoki T, Nagata Y, Negoro Y, et al: Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology 230:101-108, 2004
17. Bradley J, Graham MV, Winter K, et al: Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61:318-328, 2005
18. Guckenberger M, Heilman K, Wulf J, et al: Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): Results of a serial follow-up CT study. Radiother Oncol 85:435-442, 2007
19. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al: Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:685-692, 2008
20. Timmerman R, McGarry R, Yiannoutsos C, et al: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833-4839, 2006
21. Baumann P, Nyman J, Lax I, et al: Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 45:787-795, 2006
22. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, et al: Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 6:98, 2005
23. Lax I, Blomgren H, Larsson D, et al: Extracranial stereotactic radiosurgey of localized targets. J Radiosurg 1:135-148, 1998
24. Panettieri V, Wennberg B, Gagliardi G, et al: SBRT of lung tumours: Monte Carlo simulation with PENELOPE of dose distributions including respiratory motion and comparison with different treatment planning systems. Phys Med Biol 52: 4265-4281, 2007
25. Djarv E, Nyman J, Baumann P, et al: Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer. Acta Oncol 45:973-977, 2006
26. Schneider BJ: Non-small cell lung cancer staging: Proposed revisions to the TNM system. Cancer Imaging 8:181-185, 2008
27. Baumann P, Nyman J, Hoyer M, et al: Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer: A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol 88:359-367, 2008
28. Celli BR, Cote CG, Lareau SC, et al: Predictors of survival in COPD: More than just the FEV1. Respir Med 102:S27-S35, 2008 (suppl 1)
29. Celli BR, Cote CG, Marin JM, et al: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350:1005-1012, 2004
30. Cote CG: Surrogates of mortality in chronic obstructive pulmonary disease. Am J Med 119:54-62, 2006
31. Cote CG, Pinto-Plata VM, Marin JM, et al: The modified BODE index: Validation with mortality in COPD. Eur Respir J 32:1269-1274, 2008
32. Pignon JP, Tribodet H, Scagliotti GV, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552-3559, 2008
33. Onimaru R, Fujino M, Yamazaki K, et al: Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 70:374-381, 2008